Categories Earnings, Other Industries

What to look for when Progenics Pharma posts Q2 earnings

Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before the market opens. The results will be benefited by the revenue from the sales-based royalties under its intellectual property licensing arrangements and are recognized upon net sales of the licensed products.

Investors await for Azedra, which is used to treat pheochromocytoma and paraganglioma, ultra-rare cancers, to pull in some revenue and start contributing to the company’s growth. The company is yet to record any revenue from Azedra even though it was approved in the middle of last year. However, Progenics still rely on Relistor royalties to supply enough sustenance to thwart a fundraising event in the near-term.

The company’s sources of revenue include royalties and license fees from Bausch and other collaborators, and to a small extent, sale of research reagents. Progenics will recognize royalty income primarily based on sales of Relistor, which is used for the treatment of opioid-induced constipation.

pharma stocks
Image for representation only. Courtesy: Louis Reed/Unsplash

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer. The company’s strategy also calls for undertaking increased research and development activities and managing an increasing number of relationships with partners and other third parties, while simultaneously managing the capital necessary to support strategy.

The company is expected to incur higher R&D expenses arising from the costs associated with its clinical trials, including pharmaceutical development and manufacturing of clinical trial materials. The costs also include salaries and wages, share-based compensation and benefits, which are not tracked by the program as several of its departments support multiple development programs.

Also read: Alnylam Pharmaceuticals Q2 earnings review

Analysts expect the company to report a loss of $0.19 per share on revenue of $6.66 million for the second quarter. In comparison, during the previous year quarter, Progenics posted a loss of $0.20 per share on revenue of $3.88 million. The company has missed analysts’ expectations in all of the four quarters.

For the first quarter, Progenics reported a wider loss due to higher operating expenses. Total revenues increased by 34% year-over-year as the growth of Relistor sales drove royalty revenue higher. The one-time transition costs for Azedra manufacturing site and higher clinical and contract manufacturing costs for PyL dragged research and development expenses higher.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Earnings calendar for the week of June 14

Latest economic data evoked mixed sentiment this week -- the rebound in economic activity has raised inflation concerns while jobless claims declined for the sixth week in a row. The

GameStop (GME) Earnings: Q1 loss narrows on 25% sales growth

Video game retailer GameStop Corp. (NYSE: GME), which has become the talk of the town after the unprecedented stock rally in recent weeks, reported a narrower loss for the first

Should you invest in Steel Dynamics (STLD) stock after 78% rally?

The steel industry managed to shrug off the pandemic blues earlier than expected as the recovery in industrial activity pushed up demand. With the vaccination drive and the government’s aggressive

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top